Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Current ratio

Current ratio at other companies

Merck & Co. logo
Merck & Co.MRK
1.3×-0.1×
Delcath Systems logo
Delcath SystemsDCTH
11.2×-4.7×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
3.6×-0.6×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
Arcus Biosciences logo
Arcus BiosciencesRCUS
4×-1.3×

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-75.9%

Returns & leverage

See full
Return on equity-119.9%+46.7pp

Where this comes from

Calculated from Citius Oncology, Inc.’s reported figures.

total current assets/total current liabilities=0.5×

Based on the most recent quarter.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s current ratio?
Citius Oncology, Inc. (CTOR) reported current ratio of 0.5× in Q1 2026.
How has Citius Oncology, Inc.'s current ratio changed year-over-year?
Citius Oncology, Inc.'s current ratio increased by 37.9% year-over-year, from 0.4× to 0.5×.
What is the long-term trend for Citius Oncology, Inc.'s current ratio?
Over 2 years (2023 to 2025), Citius Oncology, Inc.'s current ratio has grown at a 23.1% compound annual growth rate (CAGR), from 0.4× to 0.6×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.